Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.

Article  Google Scholar 

Mihanfar A, Fattahi A, Nejabati HR. MicroRNA-mediated drug resistance in ovarian cancer. J Cell Physiol. 2019;234(4):3180–91.

Article  PubMed  CAS  Google Scholar 

Nasiri F, Farrokhi K, Safarzadeh Kozani P, Mahboubi Kancha M, Dashti Shokoohi S. Safarzadeh Kozani P. CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer. Front Immunol. 2023;14:1302307.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–56.

Article  PubMed  PubMed Central  Google Scholar 

Pellarin I, Belletti B, Baldassarre G. RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: a possible biomarker and therapeutic target. Med Res Rev. 2021;41(1):586–615.

Article  PubMed  CAS  Google Scholar 

Herbst AL. The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol. 1994;170(4):1099–105. discussion 105-7.

Article  PubMed  CAS  Google Scholar 

Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53.

Article  PubMed  Google Scholar 

Jin Y, Dong H, Shi Y, Bian L. Mutually exclusive alternative splicing of pre-mRNAs. Wiley Interdiscip Rev RNA. 2018;9(3):e1468.

Article  PubMed  Google Scholar 

Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature. 2010;463(7280):457–63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bonnal SC, Lopez-Oreja I, Valcarcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17(8):457–74.

Article  PubMed  Google Scholar 

Oltean S, Bates DO. Hallmarks of alternative splicing in cancer. Oncogene. 2014;33(46):5311–8.

Article  PubMed  CAS  Google Scholar 

Bonnal SC, López-Oreja I, Valcárcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17(8):457–74.

Article  PubMed  Google Scholar 

Busch A, Hertel KJ. Evolution of SR protein and hnRNP splicing regulatory factors. Wiley Interdiscip Rev RNA. 2012;3(1):1–12.

Article  PubMed  CAS  Google Scholar 

van der Feltz C, Anthony K, Brilot A, Pomeranz Krummel DA. Architecture of the spliceosome. Biochemistry. 2012;51(16):3321–33.

Article  PubMed  Google Scholar 

Will CL, Lührmann R. Spliceosomal UsnRNP biogenesis, structure and function. Curr Opin Cell Biol. 2001;13(3):290–301.

Article  PubMed  CAS  Google Scholar 

Coltri PP, Dos Santos MGP, da Silva GHG. Splicing and cancer: challenges and opportunities. Wiley Interdiscip Rev RNA. 2019;10(3):e1527.

Article  PubMed  Google Scholar 

Dredge BK, Polydorides AD, Darnell RB. The splice of life: alternative splicing and neurological disease. Nat Rev Neurosci. 2001;2(1):43–50.

Article  PubMed  CAS  Google Scholar 

Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol. 2005;6(5):386–98.

Article  PubMed  CAS  Google Scholar 

Zhang Y, Qian J, Gu C, Yang Y. Alternative splicing and cancer: a systematic review. Signal Transduct Target Ther. 2021;6(1):78.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shenasa H, Movassat M, Forouzmand E, Hertel KJ. Allosteric regulation of U1 snRNP by splicing regulatory proteins controls spliceosomal assembly. RNA. 2020;26(10):1389–99.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fu XD, Ares M Jr. Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev Genet. 2014;15(10):689–701.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Baralle FE, Giudice J. Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017;18(7):437–51.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kim HK, Pham MHC, Ko KS, Rhee BD, Han J. Alternative splicing isoforms in health and disease. Pflugers Arch. 2018;470(7):995–1016.

Article  PubMed  CAS  Google Scholar 

Tazi J, Bakkour N, Stamm S. Alternative splicing and disease. Biochim Biophys Acta. 2009;1792(1):14–26.

Article  PubMed  CAS  Google Scholar 

Wang Z, Burge CB. Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA. 2008;14(5):802–13.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu J, Lv D, Wang X, Wang R, Li X. Systematic profiling of alternative splicing events in Ovarian Cancer. Front Oncol. 2021;11:622805.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sun T, Yang Q. Chemoresistance-associated alternative splicing signatures in serous ovarian cancer. Oncol Lett. 2020;20(1):420–30.

PubMed  PubMed Central  CAS  Google Scholar 

Keren H, Lev-Maor G, Ast G. Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet. 2010;11(5):345–55.

Article  PubMed  CAS  Google Scholar 

Masciadri B, Areces LB, Carpinelli P, Foiani M, Draetta G, Fiore F. Characterization of the BUD31 gene of Saccharomyces cerevisiae. Biochem Biophys Res Commun. 2004;320(4):1342–50.

Article  PubMed  CAS  Google Scholar 

Wang Z, Wang S, Qin J, Zhang X, Lu G, Liu H, et al. Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12. Nat Commun. 2022;13(1):6246.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li Y, Chen Z, Peng J, Yuan C, Yan S, Yang N, et al. The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2. Oncogene. 2023;42(31):2386–401.

Article  PubMed  CAS  Google Scholar 

Cretu C, Schmitzová J, Ponce-Salvatierra A, Dybkov O, De Laurentiis EI, Sharma K, et al. Molecular Architecture of SF3b and Structural consequences of its Cancer-related mutations. Mol Cell. 2016;64(2):307–19.

Article  PubMed  CAS